MARKET

ARNA

ARNA

Arena Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

65.75
+1.94
+3.04%
Opening 12:32 07/14 EDT
OPEN
63.77
PREV CLOSE
63.81
HIGH
66.00
LOW
63.35
VOLUME
451.84K
TURNOVER
--
52 WEEK HIGH
69.75
52 WEEK LOW
32.95
MARKET CAP
3.72B
P/E (TTM)
-10.1856
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARNA stock price target is 77.82 with a high estimate of 95.00 and a low estimate of 60.00.

EPS

ARNA News

More
Did Hedge Funds Make The Right Call On Arena Pharmaceuticals, Inc. (ARNA) ?
Insider Monkey · 3d ago
Top Marijuana Stocks on the NASDAQ for July 2020
The marijuana industry includes companies directly related to the research, development, and distribution of cannabis products, as well as companies that indirectly support these operations. As a growing number of U.S. states and countries around the world le
Investopedia · 06/30 18:07
HC Wainwright & Co. Initiates Coverage On Arena Pharmaceuticals with Buy Rating, Announces Price Target of $90
HC Wainwright & Co. initiates coverage on Arena Pharmaceuticals (NASDAQ:ARNA) with a Buy rating and announces Price Target of $90.
Benzinga · 06/29 10:06
3 Pot Stocks Worth a Second Look
MotleyFool.com · 06/26 10:17
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · 06/18 21:01
Arena Pharmaceuticals Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors
PR Newswire · 06/15 13:30
Arena Pharmaceuticals Announces R&D Leadership Transition
PR Newswire · 06/08 21:30
Edited Transcript of ARNA earnings conference call or presentation 7-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 06/08 18:28

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.62%

Hot Stocks

Symbol
Price
%Change

About ARNA

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
More

Webull offers kinds of Arena Pharmaceuticals, Inc. stock information, including NASDAQ:ARNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARNA stock methods without spending real money on the virtual paper trading platform.